Lab
Kingsley Lane Clinical Laboratory Associates, PLLC
Kingsley Lane Clinical Laboratory Associates, PLLC was paid $588K by Medicaid between Jan 2018 and Dec 2024, across 114 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 24% of everything it billed.
33Billing provider infoKINGSLEY LANE CLINICAL LABORATORY ASSOCIATES, PLLC
PORTSMOUTH, VA 23707
PORTSMOUTH, VA 23707
33aNPI1801129549assigned 09/14/2009
33bProvider typeClinical Medical Laboratory
28Total paid$588K
24GClaims490,650
24DCodes billed114
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Virginia
Rank by total paid#24 of 78
Median peer was paid$37K
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,395 | $43K | |
| 2019 | 65,758 | $148K | |
| 2020 | 63,018 | $83K | |
| 2021 | 59,945 | $82K | |
| 2022 | 49,582 | $52K | |
| 2023 | 54,781 | $33K | |
| 2024incomplete | 178,171 | $147K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 24% | 10,860 | 9,188 | $141K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 21% | 759 | 736 | $122K |
| 80053 | Comprehensive metabolic panel | 5.5% | 46,868 | 35,123 | $32K |
| 82962 | 5.1% | 43,096 | 9,104 | $30K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.3% | 68,410 | 43,190 | $25K |
| 84484 | 4.0% | 18,659 | 13,347 | $24K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.5% | 30,091 | 15,071 | $21K |
| 83735 | 3.5% | 25,581 | 12,235 | $20K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 2,535 | 2,300 | $14K |
| 82553 | 2.4% | 4,871 | 3,860 | $14K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.9% | 5,143 | 4,935 | $11K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.9% | 5,138 | 4,931 | $11K |
102 more codes
| 81001 | 1.4% | 18,626 | $8K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.4% | 7,185 | $8K |
| 83605 | 1.3% | 7,564 | $8K | |
| 83690 | 1.3% | 12,168 | $7K | |
| 87040 | 1.0% | 5,215 | $6K | |
| 82077 | <1% | 5,106 | $5K | |
| 80050 | General health panel | <1% | 290 | $5K |
| 85730 | <1% | 5,795 | $4K | |
| 85610 | <1% | 8,158 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,349 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,210 | $4K |
| 86901 | <1% | 6,123 | $4K | |
| 83880 | <1% | 4,692 | $4K | |
| 82550 | <1% | 7,005 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 817 | $3K |
| 85027 | <1% | 9,059 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,636 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,167 | $3K |
| 84100 | <1% | 7,761 | $3K | |
| 82728 | <1% | 2,129 | $3K | |
| 81003 | <1% | 9,560 | $2K | |
| 87077 | <1% | 1,729 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 862 | $2K |
| 87210 | <1% | 2,399 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 5,203 | $1K |
| 84703 | <1% | 4,314 | $1K | |
| 86900 | <1% | 6,110 | $1K | |
| 80061 | Lipid panel | <1% | 6,041 | $1K |
| 86850 | <1% | 4,754 | $1K | |
| 80076 | <1% | 2,143 | $1K | |
| 82607 | <1% | 1,580 | $1K | |
| 81025 | <1% | 12,039 | $917.23 | |
| 87070 | <1% | 3,691 | $902.09 | |
| 83540 | <1% | 2,123 | $876.40 | |
| 85379 | <1% | 2,441 | $810.50 | |
| 87186 | <1% | 1,734 | $810.04 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 519 | $760.92 |
| 82746 | <1% | 1,001 | $687.70 | |
| 85014 | <1% | 2,884 | $570.00 | |
| 83550 | <1% | 1,446 | $561.60 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,019 | $520.00 |
| 82803 | <1% | 1,745 | $508.97 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 165 | $444.13 |
| 85018 | <1% | 2,123 | $433.92 | |
| 84439 | <1% | 1,666 | $404.79 | |
| 82330 | <1% | 1,033 | $341.55 | |
| 80202 | <1% | 810 | $332.10 | |
| 87081 | <1% | 175 | $297.48 | |
| 80069 | <1% | 397 | $281.24 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,318 | $245.63 |
| 87205 | <1% | 1,035 | $244.86 | |
| 80143 | <1% | 536 | $213.20 | |
| 84702 | <1% | 950 | $207.00 | |
| 86803 | <1% | 1,037 | $191.21 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,145 | $185.81 |
| 86923 | <1% | 314 | $180.60 | |
| 86140 | <1% | 679 | $167.47 | |
| 82570 | <1% | 1,221 | $144.30 | |
| 87147 | <1% | 755 | $117.66 | |
| 83970 | <1% | 145 | $115.80 | |
| 80179 | <1% | 519 | $114.80 | |
| 83615 | <1% | 223 | $99.96 | |
| 82140 | <1% | 187 | $69.41 | |
| 87340 | <1% | 114 | $61.98 | |
| 87088 | <1% | 363 | $54.24 | |
| 82565 | <1% | 431 | $42.18 | |
| 80177 | <1% | 54 | $42.14 | |
| 85652 | <1% | 509 | $39.59 | |
| 84132 | <1% | 819 | $39.20 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 139 | $30.23 |
| 82947 | <1% | 479 | $24.08 | |
| 87449 | <1% | 126 | $23.10 | |
| 82043 | <1% | 854 | $21.04 | |
| 86706 | <1% | 197 | $14.90 | |
| 87075 | <1% | 100 | $14.04 | |
| 86592 | <1% | 356 | $12.46 | |
| 82247 | <1% | 272 | $10.04 | |
| 80047 | <1% | 40 | $9.89 | |
| 84295 | <1% | 464 | $8.04 | |
| 80164 | <1% | 14 | $5.81 | |
| 84436 | <1% | 14 | $5.52 | |
| 82248 | <1% | 113 | $5.02 | |
| 84550 | <1% | 115 | $4.02 | |
| 84300 | <1% | 13 | $2.13 | |
| 84030 | <1% | 327 | $1.96 | |
| 85347 | <1% | 28 | $1.55 | |
| 82800 | <1% | 61 | $0.84 | |
| 84153 | 0% | 31 | $0.00 | |
| 87807 | 0% | 87 | $0.00 | |
| 88720 | 0% | 417 | $0.00 | |
| 82040 | 0% | 144 | $0.00 | |
| 86880 | 0% | 136 | $0.00 | |
| 86780 | 0% | 44 | $0.00 | |
| 86225 | 0% | 13 | $0.00 | |
| 87154 | 0% | 30 | $0.00 | |
| 84145 | 0% | 1,280 | $0.00 | |
| 84425 | 0% | 39 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 353 | $0.00 |
| 86480 | 0% | 14 | $0.00 | |
| 84156 | 0% | 73 | $0.00 | |
| 82272 | 0% | 29 | $0.00 | |
| 86235 | 0% | 122 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUMMINGS, DAVID (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Kingsley Lane Anatomic Pathology | Newport News, VA | $509K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.